Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹3,826 Cr
Revenue (TTM)
₹902 Cr
Net Profit (TTM)
₹110 Cr
ROE
10.2 %
ROCE
9.4 %
P/E Ratio
34.7
P/B Ratio
3.1
Industry P/E
45.47
EV/EBITDA
24.2
Div. Yield
0 %
Debt to Equity
0.1
Book Value
₹245.8
EPS
₹21.8
Face value
10
Shares outstanding
50,719,105
CFO
₹522.53 Cr
EBITDA
₹918.22 Cr
Net Profit
₹-1,321.63 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Orchid Pharma
| -58.1 | -6.7 | -17.6 | -29.8 | 34.6 | -- | 31.2 |
|
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
|
BSE Small Cap
| -6.0 | 4.8 | 12.4 | 7.4 | 25.0 | 37.4 | 16.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2018
|
|---|---|---|---|---|---|
|
Orchid Pharma
| 147.8 | 95.7 | -7.8 | 205.2 | -74.6 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Orchid Pharma
|
756.5 | 3,826.3 | 901.6 | 110.1 | 9.3 | 9.2 | 34.7 | 3.1 |
| 474.2 | 4,327.1 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.7 | 3.2 | |
| 302.6 | 3,296.7 | 150.8 | 48.8 | 42.1 | 20.7 | 67.6 | 13.3 | |
| 243.6 | 2,241.6 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.2 | |
| 86.3 | 2,532.6 | 2,079.2 | 101.1 | 6.3 | 6 | 25.1 | 1.5 | |
| 66.6 | 3,646.6 | 1,811.6 | 118.0 | 8.0 | 10.4 | 30.9 | 3.2 | |
| 2,188.8 | 3,636.4 | 653.4 | 183.2 | 21.2 | 20.9 | 19.8 | 6.9 | |
| 476.7 | 2,292.4 | 1,283.8 | 0.5 | 8.3 | 0 | -- | 2.1 | |
| 207.7 | 4,526.1 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 41.2 | |
| 642.0 | 4,521.1 | 2,028.9 | 150.6 | 7.5 | 6.2 | 32.9 | 1.9 |
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical... ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is based in Narsinghpur, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited. Read more
Incorporated
1992
Chairman
Ram Gopal Agarwal
Managing Director
Manish Dhanuka
Headquarters
Chengalpattu, Tamil Nadu
Website
Looking for more details about Orchid Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Orchid Pharma Ltd stood at ₹ 1,635 Cr as on 31-Dec-24
The share price of Orchid Pharma Ltd is ₹756.50 (NSE) and ₹754.40 (BSE) as of 23-May-2025 IST. Orchid Pharma Ltd has given a return of 34.59% in the last 3 years.
Orchid Pharma Ltd has a market capitalisation of ₹ 3,826 Cr as on 23-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Orchid Pharma Ltd is 3.07 times as on 23-May-2025, a 3% discount to its peers’ median range of 3.16 times.
The P/E ratio of Orchid Pharma Ltd is 34.68 times as on 23-May-2025, a 24% discount to its peers’ median range of 45.47 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Orchid Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Orchid Pharma Ltd.
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services. It also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is based in Narsinghpur, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
The promoter of Orchid Pharma Ltd is Dhanuka Laboratories Limited. Dhanuka Laboratories Limited owns 69.84 per cent of the total equity. The chairman of the company is Ram Gopal Agarwal , and the managing director is Manish Dhanuka..
There is no promoter pledging in Orchid Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
4,526
|
|
|
4,521
|
|
|
4,327
|
|
|
3,647
|
|
|
3,636
|
|
|
3,297
|
|
|
2,533
|
|
|
2,292
|
|
|
2,242
|
| Orchid Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
9.22
|
|
Operating margin(%)
|
9.32
|
|
Net Margin(%)
|
11.73
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Orchid Pharma Ltd was ₹110 Cr.
₹33.85
(
